Đề thi VSTEP Full C1 — Nghiên cứu học thuật & Thách thức toàn cầu

Adaptation research in climate-vulnerable nations has historically been underfunded relative to its potential impact. While mitigation strategies dominate global climate budgets, adaptation studies—particularly those addressing agricultural resilience and water security—receive a disproportionately small share of research investment. Low-income countries that contribute least to global emissions often face the highest research gaps, exacerbating cycles of vulnerability. A growing body of literature suggests that participatory research models, which involve local communities in defining research priorities, produce more contextually relevant findings than externally imposed frameworks. Farmer-led trials in sub-Saharan Africa have identified drought-resistant crop varieties that top-down agronomic research had overlooked for decades. Similarly, indigenous knowledge systems are increasingly recognized as complementary to formal scientific methods, offering longitudinal datasets on ecological change that instrumental records cannot replicate. Critics caution against romanticizing local knowledge or assuming that community participation alone resolves power asymmetries. Sustainable adaptation research requires institutional capacity-building, sustained funding, and equitable North-South partnerships. Without these structural supports, even well-designed participatory projects risk becoming short-lived interventions that fail to influence long-term policy.

The COVAX initiative, launched in 2020 by Gavi, the Vaccine Alliance, the World Health Organization, and CEPI, represented the most ambitious global effort to ensure equitable access to COVID-19 vaccines. Its central aim was to procure and distribute two billion doses by the end of 2021, prioritizing low- and middle-income countries that might otherwise be excluded from bilateral deals between wealthy nations and pharmaceutical companies. Despite securing substantial funding from donor governments, COVAX faced significant structural challenges. Vaccine hoarding by wealthy countries, export restrictions, and supply chain disruptions repeatedly delayed shipments. By mid-2021, COVAX had delivered only a fraction of its target. Critics argued that its voluntary funding model and reliance on donations left it vulnerable to the same inequities it sought to address. Nevertheless, COVAX succeeded in delivering over a billion doses to 190 economies by early 2022, demonstrating that multilateral vaccine distribution is operationally feasible. The initiative also strengthened regulatory capacity in recipient countries and accelerated the development of regional manufacturing hubs. Researchers now view COVAX as a critical case study in global health governance—illustrating both the potential and the limits of voluntary cooperation in addressing transnational health crises.